Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2022-N-1349]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 31 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of August 11, 2022.
 FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, 
                        *Martha.Nguyen@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Application No.
Drug
ApplicantANDA 040846
Hydrocodone Bitartrate and Acetaminophen Tablets, 325 milligrams (mg); 2.5 mg
Mikart, LLC, 1750 Chattahoochee Ave. NW, Atlanta, GA 30318.ANDA 040851
Benzonatate Capsules, 100 mg, 150 mg, and 200 mg
Do.ANDA 072903
Ibuprofen Tablets, 200 mg
ANI Pharmaceuticals, Inc., 210 Main St. West, Baudette, MN 56623.ANDA 073519
Tolmetin Sodium Capsules, Equivalent to (EQ) 400 mg base
Do.ANDA 074267
Guanabenz Acetate Tablets, EQ 4 mg base and EQ 8 mg base
Do.ANDA 074498
Indapamide Tablets, 1.25 mg and 2.5 mg
Do.ANDA 074840
Etodolac Capsules, 200 mg and 300 mg
Do.ANDA 074844
Etodolac Capsules, 200 mg and 300 mg
Do.ANDA 075212
Ranitidine Hydrochloride (HCl) Tablets, EQ 75 mg base
Do.ANDA 076030
Flecainide Acetate Tablets, 50 mg, 100 mg, and 150 mg
Do.ANDA 076086
Fluconazole Tablets, 50 mg, 100 mg, 150 mg, and 200 mg
Do.ANDA 077426
Ranitidine HCl Tablets, EQ 150 mg base and EQ 300 mg base
Do.ANDA 077641
Zonisamide Capsules, 25 mg, 50 mg, and 100 mg
Do.ANDA 077979
Alprazolam Extended Release Tablets, 0.5 mg, 1 mg, 2 mg, and 3 mg
Do.ANDA 085269
Meclizine HCl Tablets, 12.5 mg
Do.ANDA 085740
Meclizine HCI Tablets, 25 mg
Do.ANDA 087296
Chlorthalidone Tablets, 25 mg
Do.ANDA 088164
Chlorthalidone Tablets, 25 mg
Do.ANDA 088641
Glucamide Tablets, 250 mg
Do.ANDA 088732
Meclizine HCl Tablets, 12.5 mg
Do.ANDA 088768
Chlorpropamide Tablets, 100 mg
Do.ANDA 088826
Chlorpropamide Tablets, 250 mg
Do.ANDA 090572
Cetirizine HCl, Syrup 5 mg/5 milliliters (mL)
Tris Pharma, Inc., 2031 U.S. Hwy. 130, Suite D, Monmouth Junction, NJ 08852.ANDA 090906
Levetiracetam Tablets, 250 mg, 500 mg, 750 mg, and 1 gram (gm)
Alvogen PB Research and Development, U.S. Agency for Lotus Pharmaceutical Co., Ltd., Nantou Plant, 44 Whippany Rd., Suite 300, Morristown, NJ 07960.ANDA 201944
Potassium Chloride Extended Release Capsules, 8 milliequivalent (mEq) and 10 mEq
Tris Pharma, Inc.ANDA 202095
Levetiracetam Extended Release Tablets, 500 mg and 750 mg
Alvogen PB Research and Development, U.S. Agency for Lotus Pharmaceutical Co., Ltd.ANDA 202246
Levonorgestrel Tablets, 1.5 mg
Alvogen, Inc., 44 Whippany Rd., Suite 300, Morristown, NJ 07960.ANDA 203298
Calcium Acetate Capsules, 667 mg
Alvogen PB Research and Development, U.S. Agency for Lotus Pharmaceutical Co., Ltd.ANDA 204180
Amiloride HCl Tablets, 5 mg
USpharma Windlas, LLC, 115 Blue Jay Dr., Suite 101, Liberty, MO 64068.ANDA 205442
Linezolid Injection, 600 mg/300 mL (2 mg/mL)
Hospira, Inc., 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.ANDA 205790
Prasugrel Tablets, EQ 5 mg base and EQ 10 mg base
USpharma Windlas, LLC.
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of August 11, 2022. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and 
                    ( print page 41323)
                    (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on August 11, 2022 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: July 1, 2022. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2022-14798 Filed 7-11-22; 8:45 am] BILLING CODE 4164-01-P